Matinas BioPharma Holdings Inc banner
M

Matinas BioPharma Holdings Inc
AMEX:MTNB

Watchlist Manager
Matinas BioPharma Holdings Inc
AMEX:MTNB
Watchlist
Price: 0.549 USD 9.8%
Market Cap: $3.5m

During the last 3 months Matinas BioPharma Holdings Inc insiders have not bought any shares, and have not sold any shares. The stock price has dropped by 7% over this period (open performance analysis).

The last transaction was made on Apr 8, 2025 by Sanitam Partners Llc , who bought 703k USD worth of MTNB shares.

Last Transactions:
Pembroke & Partners Llc
$+492k
Sanitam Partners Llc
$+703k
Eide Robert J
$+492k
Stern Adam K
$+332
Lepore Patrick G
$+1.5k
Jabbour Jerome D
$+130
Stern Adam K
$+130
Kucinski Keith A
$+1.4k
Kucinski Keith A
$+876.1
Lepore Patrick G
$+2.1k
Ende Eric J
$+264
Jabbour Jerome D
$+199.5
Stern Adam K
$+145.4
Ende Eric J
$+273
Lepore Patrick G
$+1.4k
Stern Adam K
$+240
Jabbour Jerome D
$+199.8
Stern Adam K
$+320
Stern Adam K
$+246
Stern Adam K
$+356
Stern Adam K
$+1.5k
Conrad Herbert J
$+482.3
Lepore Patrick G
$+1.9k
Stern Adam K
$+2.9k
Wikler Matthew
$+0
Mannino Raphael J
$+0
Conrad Herbert J
$+2k
Scibetta James S
$+0
Stern Adam K
$+2k
Ende Eric J
$+0
Jabbour Jerome D
$+0
Mannino Raphael J
$+141
View All Transactions

During the last 3 months Matinas BioPharma Holdings Inc insiders have not bought any shares, and have not sold any shares. The stock price has dropped by 7% over this period (open performance analysis).

The last transaction was made on Apr 8, 2025 by Sanitam Partners Llc , who bought 703k USD worth of MTNB shares.

Sold
0-3
months
0 USD
0
3-6
months
0 USD
0
6-9
months
0 USD
0
9-12
months
0 USD
0
Bought
0-3
months
No Insider Transactions
0
0 USD
3-6
months
No Insider Transactions
0
0 USD
6-9
months
No Insider Transactions
0
0 USD
9-12
months
No Insider Transactions
0
0 USD

Matinas BioPharma Holdings Inc
Insider Trading Chart

Matinas BioPharma Holdings Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Matinas BioPharma Holdings Inc
Last Insider Transactions

Global
Insiders Monitor

Matinas BioPharma Holdings Inc
Glance View

Market Cap
3.5m USD
Industry
Biotechnology

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Bedminster, New Jersey and currently employs 34 full-time employees. The company went IPO on 2014-06-03. The firm is focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology (LNC Platform) to maximize global clinical impact and patient access. The Company’s lead anti-fungal product candidate, MAT2203, is an application of its LNC Platform to a broad spectrum and potent anti-fungal drug called amphotericin B. Its second clinical-stage LNC-based product candidate is MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin, which may be used to treat different types of multidrug-resistant bacteria, including NTM, as well as various multidrug-resistant gram-negative and intracellular bacterial infections. The company also has internal discovery programs ongoing in the formulation and delivery of small oligonucleotides, namely antisense oligonucleotides (ASOs) and silencing or short interfering RNAs (siRNAs).

MTNB Intrinsic Value
Not Available

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett